A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers
NCT ID: NCT05695560
Last Updated: 2023-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
12 participants
OBSERVATIONAL
2023-02-24
2023-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The survey is planned to be done in two phases: The first phase will be directed at adult participants; the second phase will focus on children and teenagers. At the end of the first phase the Sponsor will decide if the second phase will be started.
Participants and their caregivers will be asked to answer a set of questions either using an online questionnaire or through interviews. The participant/caregiver's perception, experience, satisfaction, and unmet needs, and need for new treatments or new indications will be determined based on their responses to the questions.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will enroll approximately 49 patients, taking into scope both the participant's and caregiver's perspectives, and is planned to be conducted in two phases:
Phase 1: Adult Participants Phase 2: Pediatric Participants The decision to proceed with Phase 2 will be determined at the completion of Phase 1.
This multi-center trial will be conducted in Canada. The overall time for data collection in this study is approximately 9 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1: Adult Participants
Adult participants with severe VWD (self-bleeding assessment tool \[BAT\] score ≥10) and their caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform.
No Intervention
As this is an observational study, no intervention will be administered.
Phase 2: Pediatric Participants
Pediatric participants with severe VWD (self-pediatric bleeding questionnaire \[PBQ\] score of ≥3 for at least one symptom and caregivers will be enrolled as per protocol specifications. Data will be collected from participants via questionnaire, semi-structured interviews, and focus groups using a virtual platform. The decision to proceed with Phase 2 will be determined following completion of Phase 1.
No Intervention
As this is an observational study, no intervention will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention
As this is an observational study, no intervention will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult participants (age ≥18 years) with severe VWD (self-BAT ≥10)
* Participants who have received von Willebrand factor (VWF) treatment, either for on-demand treatment, regular prophylaxis, or situational prophylaxis (e.g., surgery) within the last 5 years
* For caregivers: Current caregiver of participants with severe VWD
* For caregivers and participants:
* Fluent in English or French
* Consent to participate in an individual phone interview and to fill self-administered questionnaires
* Access to technology (Internet and email)
* Consent to participate in a virtual focus group with an audio recording of the session.
* Phase 2:
* Same as above for participants pediatric participants (age \<18 years) with severe VWD (self-PBQ score of ≥3 for at least one symptom).
Exclusion Criteria
* Participants or caregivers of participants who do not have severe symptoms of VWD
* Pediatric participants (age \<18 years)
* Participants who have not received any treatment (on-demand, regular or situational prophylaxis) within the last five years
* Participants who are successfully treated with desmopressin or anti-fibrinolytic medications
* Participants with inherited or acquired hemostatic or bleeding disorders other than congenital VWD (self-reported)
* Participants and caregivers of participants who show cognitive impairment (as assessed by the research nurse at the time of screening)
* Participants and caregivers who are qualified as health care practitioners currently working in a health-care capacity (e.g., physician, nurse, or healthcare aid)
* Participants or caregivers who do not reside in Canada
* Current or past participation within the last 12 months in a clinical trial
* Phase 2: Same as above excluding participants of ≥18 years of age
0 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
YolaRx Consultants
Montreal, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain more information on the study, click here/on this link.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAK-577-4002
Identifier Type: -
Identifier Source: org_study_id